PRLD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PRLD ▼ -3.77% at T+20d

LONG call ✗ call lost -3.77% · α vs SPY -7.97% · entry $4.51 → $4.34

Next anchor: T+60d in 5w

Currently $4.49 · -0.44% from $4.51 entry

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

+2.44%

call +2.44% · α +3.09%

$4.62

settled 8w ago

T+5d

+0.22%

call +0.22% · α -0.69%

$4.52

settled 7w ago

T+20d

-3.77%

call -3.77% · α -7.97%

$4.34

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Prelude Therapeutics announced positive preclinical data for its lead candidate PRT13722, a first-in-class, selective KAT6A degrader for HR+/HER2- breast cancer, showing complete tumor regressions and an improved safety profile. The company remains on track to file an IND in mid-2026 and initiate a Phase 1 trial in the second half of 2026. While the data are promising, they are preclinical and not yet validated in humans.

Actionable Insight

Traders should monitor upcoming IND filing in mid-2026 and any early clinical trial announcements. While preclinical results are encouraging, the stock reaction may reflect heightened expectations—position accordingly ahead of potential clinical milestones or setbacks.

Key Facts

PRT13722 is a first-in-class, orally bioavailable, highly selective KAT6A degrader.
Preclinical data show complete tumor regressions in HR+/HER2- breast cancer models, both in treatment-naive and therapy-experienced settings.
PRT13722 demonstrates synergy with standard therapies (ET, CDK4/6i, PI3Kαi) and improved hematological safety vs. prifetrastat.
IND filing expected mid-2026; Phase 1 trial initiation planned for 2H 2026.
Data presented at AACR Annual Meeting 2026.

Financial Impact

No direct financial impact disclosed; potential long-term value creation if clinical development succeeds.

pipeline_valueR&D_progressinvestor_sentiment

Risk Factors

Preclinical results may not translate to clinical efficacy or safety in humans.
Development timeline delays are possible despite current guidance.
High valuation risk given small market cap ($280M) and early-stage pipeline.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3276794

8 reports for PRLD

T+1T+5T+20T+60

100% Hit rate 5 of 5 directional calls best @ T+1▲ +22.48%Apr 21, 2026

Filters

Reports for PRLD — sortable, filterable
	Type				Now
May 12, 2026 4w ago	8-K BULLISH ★ 6/10	$4.64 $4.34	▼ −6.47%	▼ −6.54%	$4.49 (−3.23%)
May 12, 2026 4w ago	Press Release BULLISH ★ 7/10	$4.64 $4.34	▼ −6.47%	▼ −6.54%	$4.49 (−3.23%)
Apr 28, 2026 6w ago	3 BULLISH ★ 6/10	$4.27 $4.67	▲ +9.37%	▲ +6.26%	$4.49 (+5.15%)
Apr 21, 2026 7w ago	Insider Cluster BULLISH ★ 8/10	$4.27 $4.84	▲ +13.35%	▲ +10.24%	$4.49 (+5.15%)
Apr 20, 2026 7w ago	8-K BULLISH ★ 7/10	$4.51 $4.52	▲ +0.22%	▼ −0.69%	$4.49 (−0.44%)
Apr 20, 2026 7w ago	Press Release BULLISH ★ 7/10	$4.51 $4.52	▲ +0.22%	▼ −0.69%	$4.49 (−0.44%)
Apr 15, 2026 8w ago	8-K NEUTRAL ★ 3/10	$5.52 $4.31	▼ −21.92%	▼ −23.56%	$4.49 (−18.66%)
Mar 10, 2026 13w ago	Press Release MIXED ★ 6/10	$3.60 $3.43	▼ −4.72%	▼ −3.82%	$4.49 (+24.72%)

US Market Status

Market Closed — Opens Mon (48h 14m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access